(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 August 2022 (11.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/170002 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
A61K 31/4745 (2006.01)

(21) International Application Number:
PCT/US2022/015157

(22) International Filing Date:
03 February 2022 (03.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/145,367 03 February 2021 (03.02.2021) US

(71) Applicants: **SEAGEN INC.** [US/US]; 21823 30th Drive SE, Bothell, Washington 98021 (US). **REGENTS OF THE UNIVERSITY OF MINNESOTA** [US/US]; 200 Oak Street SE, Office for Technology Commercialization, Suite 280, Minneapolis, Minnesota 55455 (US).

(72) Inventors: **WANG, Kung-Pern**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **SMITH, Alyson**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **NEUMANN, Christopher Scott**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **GARDAI, Shyra J.**; c/o Seagen Inc., 21823 30th Drive SE, Bothell, Washington 98021 (US). **FERGUSON, David**; c/o Regents of the University of Minnesota, 200 Oak Street SE, Office for Technology Commercialization, Suite 280, Minneapolis, Minnesota 55455 (US).

(74) Agent: **HARWOOD, Melissa M.** et al.; DLA Piper LLP, 701 Fifth Avenue, Suite 6900, Seattle, Washington 98104-7029 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES

(57) Abstract: The present disclosure provides, *inter alia*, antibody drug conjugates that are useful in treating various diseases such as cancer. The antibody drug conjugates can be configured to elicit tumor site-specific responses, including tumor microenvironment immunostimulation, while limiting off-target and systemic effects. In certain embodiments disclosed herein, the antibody drug conjugates are configured to release payloads following internalization by immune, cancer, or tumor associated cells.

WO 2022/170002 A1